 |
MediTox Headquarters (Photo = MediTox) |
[Alpha Biz= Kim Jisun] Seoul, September 23, 2025 – Meditox announced that it will challenge the KRW 456.05 million (approx. USD 330,000) fine imposed by Korea’s Ministry of Food and Drug Safety (MFDS) in relation to the manufacturing of its botulinum toxin product, Meditoxin.
The company stated on September 23 that it does not accept the administrative penalty issued the previous day and will pursue legal remedies.
Meditox has a history of legal victories in disputes with MFDS. The company previously won both the first and second trial rulings over ingredient changes in Meditoxin, and in March 2025, the Supreme Court dismissed MFDS’s appeal, confirming Meditox’s victory. At the time, the Supreme Court overturned MFDS’s earlier decision to revoke product licenses and suspend sales of three Meditoxin products (50, 100, and 150 units).
A Meditox spokesperson said,
“We will clarify the truth regarding this administrative action by MFDS through proper legal procedures.”
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
